Management of ST-Elevation Myocardial Infarction in High-Risk Settings

Int J Angiol. 2021 Mar;30(1):53-66. doi: 10.1055/s-0041-1723941. Epub 2021 Feb 12.

Abstract

Despite the widespread adoption of primary percutaneous intervention and modern antithrombotic therapy, ST-segment elevation myocardial infarction (STEMI) remains the leading cause of death in the United States and remains one of the most important causes of morbidity and mortality worldwide. Certain high-risk patients present a challenge for diagnosis and treatment. The widespread adoption of primary percutaneous intervention in addition to modern antithrombotic therapy has resulted in substantial improvement in the short- and long-term prognosis following STEMI. In this review, we aim to provide a brief analysis of the state-of-the-art treatment for patients presenting with STEMI, focusing on cardiogenic shock, current treatment and controversies, cardiac arrest, and diagnosis and treatment of mechanical complications, as well as multivessel and left main-related STEMI.

Keywords: STEMI; cardiac arrest; cardiogenic shock; multivessel; myocardial infarction.

Publication types

  • Review